Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414362 · ClinicalTrials.gov registry record
Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT00414362 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 1,000 participants.
The verdict
NCT00414362 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli. The current IDSA guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the first line agents. However, over use of this empiric regimen could result in in appropriate treatment of bacteremia.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2007-02 |
| Est. Completion | 2017-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414362
The ClinicalTrials.gov registry entry for NCT00414362 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00414362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00414362 about?
NCT00414362 is a clinical study titled "Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin". The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli. The current IDSA guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the firs...
What is the current status of trial NCT00414362?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2007-02. Estimated completion is 2017-06.
Who is sponsoring clinical trial NCT00414362?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.